Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MiNK Therapeutics, Inc. INKT
$1.69
+$0.07 (4.32%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
57648190.00000000
-
week52high
4.32
-
week52low
0.85
-
Revenue
2704743000
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-0.54000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 10 авг 2022 г. | |
| B. Riley Securities | Buy | Buy | 24 янв 2022 г. |
| William Blair | Outperform | 09 ноя 2021 г. | |
| Evercore ISI Group | Outperform | 09 ноя 2021 г. | |
| Baird | Outperform | 09 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ARMEN GARO H | A | 200000 | 200000 | 16 янв 2023 г. |
| van Dijk Marcus Antonius | D | 27363 | 24265 | 09 янв 2023 г. |
| van Dijk Marcus Antonius | A | 51628 | 51628 | 09 янв 2023 г. |
| van Dijk Marcus Antonius | A | 15000 | 15000 | 09 янв 2023 г. |
| Buell Jennifer | A | 500000 | 500000 | 09 янв 2023 г. |
| Buell Jennifer | A | 380715 | 171990 | 09 янв 2023 г. |
| WIINBERG ULF | A | 36052 | 5364 | 01 дек 2022 г. |
| Baldoni John | A | 16482 | 5508 | 01 дек 2022 г. |
| Ryan Barbara | A | 20351 | 6801 | 01 дек 2022 г. |
| Corvese Brian | A | 298795 | 6849 | 01 дек 2022 г. |
Новостная лента
MiNK Therapeutics Undervalued Given Potential Of Platform
Seeking Alpha
05 дек 2022 г. в 22:43
MiNK Therapeutics reported positive results from two Phase 1 trials. Invariant Natural Killer T cells offer advantages over standard therapies.
MiNK Therapeutics, Inc. (INKT) Q3 2022 Earnings Call Transcript
Seeking Alpha
06 ноя 2022 г. в 12:55
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q3 2022 Earnings Conference Call November 2, 2022 ET Company Participants Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Jack Allen - Baird Operator Good morning, and welcome to MiNK Therapeutics' Third Quarter 2022 Conference Call and Webcast.
MiNK Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewsWire
31 авг 2022 г. в 09:00
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September:
MiNK Therapeutics, Inc.'s (INKT) CEO Jennifer Buell on Q2, 2022 Results.
Seeking Alpha
13 авг 2022 г. в 03:50
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q2 2022 Earnings Conference Call August 9, 2022 11:00 AM ET Company Participants Kimberly Ha - Head of Investor Relations Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Kalpit Patel - B. Riley Securities Jack Allen - Baird Matthew Phipps - William Blair Operator Good day, and welcome to the MiNK Therapeutics Second Quarter 2022 Earnings Conference Call.
MiNK Therapeutics A Bargain For Potential Cell Therapies
Seeking Alpha
23 июн 2022 г. в 10:56
iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells.